Replies to post #236714 on Biotech Values

[vinmantoo]

Still, there could end up being a long-lasting market for COVID-19 antivirals, so this program seems to have a reasonable cost/benefit tradeoff.

I think that is a safe bet, and such antivirals could be useful for other Sars viruses down the road, at least for a starting point.